Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Reliably Assessing Duration of Protection for COVID-19 Vaccines

Dan-Yu Lin, Donglin Zeng, Yu Gu, Thomas R Fleming, Philip R Krause
doi: https://doi.org/10.1101/2021.12.22.21268201
Dan-Yu Lin
1University of North Carolina at Chapel Hill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lin@bios.unc.edu phil@drkrause.com
Donglin Zeng
1University of North Carolina at Chapel Hill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu Gu
1University of North Carolina at Chapel Hill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas R Fleming
2University of Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip R Krause
3US Food and Drug Administration
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lin@bios.unc.edu phil@drkrause.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Decision-making about booster dosing for COVID-19 vaccine recipients hinges on reliable methods for evaluating the longevity of vaccine protection. We show that modeling of protection as a piecewise linear function of time since vaccination for the log hazard ratio of the vaccine effect provides more reliable estimates of vaccine effectiveness at the end of an observation period and also more reliably detects plateaus in protective effectiveness as compared with the traditional method of estimating a constant vaccine effect over each time period. This approach will be useful for analyzing data pertaining to COVID-19 vaccines and other vaccines where rapid and reliable understanding of vaccine effectiveness over time is desired.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

National Institutes of Health grant R01 AI029168

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

There are no actual data in this manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 27, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Reliably Assessing Duration of Protection for COVID-19 Vaccines
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Reliably Assessing Duration of Protection for COVID-19 Vaccines
Dan-Yu Lin, Donglin Zeng, Yu Gu, Thomas R Fleming, Philip R Krause
medRxiv 2021.12.22.21268201; doi: https://doi.org/10.1101/2021.12.22.21268201
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Reliably Assessing Duration of Protection for COVID-19 Vaccines
Dan-Yu Lin, Donglin Zeng, Yu Gu, Thomas R Fleming, Philip R Krause
medRxiv 2021.12.22.21268201; doi: https://doi.org/10.1101/2021.12.22.21268201

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1103)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (504)
  • Epidemiology (9787)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2323)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1566)
  • Health Policy (737)
  • Health Systems and Quality Improvement (606)
  • Hematology (238)
  • HIV/AIDS (507)
  • Infectious Diseases (except HIV/AIDS) (11660)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2149)
  • Nursing (134)
  • Nutrition (339)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1184)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (220)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (313)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2192)
  • Public and Global Health (4676)
  • Radiology and Imaging (782)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (625)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (211)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)